Caribou Biosciences (CRBU) Stock Statistics & Valuation Metrics

Caribou Biosciences has a market cap or net worth of $71.99M. The enterprise value is -$38.09M.

Caribou Biosciences has 93,004,600 shares outstanding. The number of shares has decreased by -2.65% in one year.

Caribou Biosciences’s return on equity (ROE) is -0.59 and return on invested capital (ROIC) is -58.65%.

The current PE Ratio of Caribou Biosciences is -0.96. Caribou Biosciences’s PEG ratio is -0.05.

In the last 12 months, Caribou Biosciences had revenue of 9.99M and earned -149.10M in profits. Earnings per share was -1.65.

In the last 12 months, operating cash flow was -138.20M and capital expenditures -4.88M, giving a free cash flow of -143.08M billion.

Caribou Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―

Caribou Biosciences upcoming earnings date is May 13, 2025, TBA Not Confirmed.

Caribou Biosciences as a current ratio of 7.16, with Debt / Equity ratio of 10.47%

In the past 12 months, Caribou Biosciences has paid -9.00K in taxes.

Caribou Biosciences EV to EBITDA ratio is -0.92, with an EV/FCF ratio of -1.07.

Caribou Biosciences has $209.54M in cash and marketable securities with $26.49M in debt, giving a net cash position of -$183.05M billion.

Gross margin is 84.33%, with operating margin of -1667.16%, and net profit margin of -1491.95%.

The average price target for Caribou Biosciences is $8.25, which is 11.43% higher than the current price. The consensus rating is Strong Buy